Seeking Alpha

Contextuall's  Instablog

Contextuall
Send Message
Contextuall was founded on the belief that people’s online activities are a leading indicator of what they plan to do in the future. - Before you buy a car, you search for the best deals online - If you just lost your job, you tweet about it - If you’re visiting your local shopping mall, you... More
My company:
Contextuall
My blog:
Contextuall Free Reports
  • Trade Picks: List Of Biotech Stocks In Rally Mode, Showing Strong Gains (SMA50 Vs SMA200) (Dec-18) 0 comments
    Dec 18, 2012 7:32 PM | about stocks: NKTR, SNTS, BIIB, CELG, ILMN, AMGN, ARNA, BMRN, GILD, ALXN, ARRY, ARIA, SGEN, NPSP, PDLI, AFFY, SRPT

    Screen Criteria:

    List of Biotech stocks, with the 50-day simple moving average (SMA50) trading above the 200-day simple moving average (SMA200). (Link to original post)

    Ranking of This List:

    This list is currently ranked 176 out of 284 lists tracked by Contextuall.com, i.e. the company characteristics described below have outperformed 38.03% of lists in Contextuall's coverage universe.

    Average Weekly Returns:

    Average 1-Week Return of All Stocks Mentioned Below: -1.58%

    Average 1-Month Return of All Stocks Mentioned Below: 3.63%

    Analysis of List Alpha:

    Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Week): 10 out of 17 (58.82%)

    Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Month): 6 out of 17 (35.29%)

    (List sorted by monthly performance, from best to worst)

    1. Nektar Therapeutics (NASDAQ:NKTR): Engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. 50-day SMA at 8.17 vs. 200-day SMA at 8.10 (current price at 6.99).

    2. Santarus (NASDAQ:SNTS): Engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. 50-day SMA at 9.50 vs. 200-day SMA at 7.34 (current price at 10.95).

    3. Biogen Idec Inc. (NASDAQ:BIIB): Develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. 50-day SMA at 146.45 vs. 200-day SMA at 139.83 (current price at 153.42).

    4. Celgene Corporation (NASDAQ:CELG): Develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. 50-day SMA at 77.05 vs. 200-day SMA at 72.87 (current price at 80.03).

    5. Illumina Inc. (NASDAQ:ILMN): Develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. 50-day SMA at 49.99 vs. 200-day SMA at 45.97 (current price at 51.85).

    6. Amgen Inc. (NASDAQ:AMGN): Develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. 50-day SMA at 86.91 vs. 200-day SMA at 77.13 (current price at 89.29).

    7. Arena Pharmaceuticals (NASDAQ:ARNA): Focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. 50-day SMA at 8.75 vs. 200-day SMA at 7.08 (current price at 9.47).

    8. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. 50-day SMA at 45.28 vs. 200-day SMA at 39.30 (current price at 49.27).

    9. Gilead Sciences Inc. (NASDAQ:GILD): Engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. 50-day SMA at 71.06 vs. 200-day SMA at 57.49 (current price at 75.85).

    10. Alexion Pharmaceuticals (NASDAQ:ALXN): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. 50-day SMA at 98.08 vs. 200-day SMA at 97.57 (current price at 97.29).

    11. Array BioPharma (NASDAQ:ARRY): Focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. 50-day SMA at 4.14 vs. 200-day SMA at 4.08 (current price at 3.74).

    12. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. 50-day SMA at 22.36 vs. 200-day SMA at 19.03 (current price at 20.18).

    13. Seattle Genetics Inc. (NASDAQ:SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. 50-day SMA at 25.11 vs. 200-day SMA at 23.61 (current price at 23.92).

    14. NPS Pharmaceuticals (NASDAQ:NPSP): Engages in the development specialty therapeutics for gastrointestinal and endocrine disorders. 50-day SMA at 9.59 vs. 200-day SMA at 8.11 (current price at 9.7).

    15. PDL BioPharma (NASDAQ:PDLI): Engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. 50-day SMA at 7.68 vs. 200-day SMA at 6.73 (current price at 7.45).

    16. Affymax (OTCQB:AFFY): Engages in the development of drugs for the treatment of serious and life-threatening conditions. 50-day SMA at 23.85 vs. 200-day SMA at 17.06 (current price at 22.3).

    17. Sarepta Therapeutics (NASDAQ:SRPT): 50-day SMA at 26.90 vs. 200-day SMA at 12.52 (current price at 26.1).

Back To Contextuall's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • $$ [new post] Intelligent Machines Reading the News, and Predicting the Future http://bit.ly/16juxxB
    Apr 30, 2013
  • $$ Just launched a graphical news sentiment tool for major companies--any thoughts? Please let us know :) http://bit.ly/ZlN89l
    Apr 23, 2013
  • $$ List of most bullish sectors and industries, based on aggregated tweets over last 24hours http://bit.ly/XIyyI0
    Apr 2, 2013
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.